menu
    • menu
    [{"orgOrder":0,"company":"Actithera","sponsor":"M Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2025","type":"Series A Financing","leadProduct":"Undisclosed","moa":"FAP","graph1":"Oncology","graph2":"Preclinical","graph3":"Actithera","amount2":0.080000000000000002,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Actithera \/ M Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Actithera \/ M Ventures"},{"orgOrder":0,"company":"Actithera","sponsor":"Actithera","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Radiolabeled Compound","year":"2025","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Actithera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actithera \/ Actithera","highestDevelopmentStatusID":"3","companyTruncated":"Actithera \/ Actithera"}]

    Find Clinical Drug Pipeline Developments & Deals by Actithera

    Menu

    Actithera

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Actithera

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Actithera

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Recipient : Yeda

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Actithera Exclusive Rights to Covalent Chemistry Tech for Radiopharmaceuticals

                            Details : Through the licensing deal, an undisclosed radiolabeled compound will be utilized for cancer treatment, advancing oncology research.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Undisclosed

                            October 14, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Recipient : Yeda

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Actithera

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Actithera

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : M Ventures

                            Deal Size : $75.5 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Actithera Raises $75.5M in Oversubscribed Series A Financing

                            Details : The proceeds will support clinical development of Actithera's fibroblast activation protein (FAP)-targeting candidate and pipeline expansion, which is being evaluated for trreating neoplasms.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Undisclosed

                            July 09, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : M Ventures

                            Deal Size : $75.5 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth